We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Announces Clinical Milestone in Ophthalmology Program
News

MorphoSys Announces Clinical Milestone in Ophthalmology Program

MorphoSys Announces Clinical Milestone in Ophthalmology Program
News

MorphoSys Announces Clinical Milestone in Ophthalmology Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Clinical Milestone in Ophthalmology Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that it has received a milestone payment from Novartis in connection with the clinical trial application (CTA/IND) and projected initiation of a Phase 1 clinical trial.

The HuCAL-derived, fully human antibody will be developed in the therapeutic area of ophthalmology.

"Our pipeline of therapeutic antibody candidates is more advanced than ever. Today's news marks the first of up to five clinical milestones from our collaborators that we expect to see during the course of the year," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

Dr. Sproll continued, "In total, our collaboration with Novartis has resulted in seven clinical programs to date, three currently being in Phase 1 and four in Phase 2."

Current Status of MorphoSys's Pipeline:
In total, MorphoSys's pipeline now comprises 21 clinical programs.

Of these, 17 are partnered programs, of which nine are in Phase 1, seven are in Phase 2 and one is in Phase 2/3 development.

The remaining four are the Company's proprietary programs MOR103, which has concluded a Phase 1b/2a trial for rheumatoid arthritis and is currently being evaluated in a Phase 1b trial in multiple sclerosis; MOR208, which has concluded a Phase 1 trial for chronic lymphocytic leukemia and will be evaluated in Phase 2 trials in B-ALL and NHL; and MOR202, which is in a Phase 1/2a trial for multiple myeloma.

Advertisement